CELG

Welcome to the 'CELG' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'CELG'.

Latest blogosphere posts tagged “CELG”

• Celgene remains in an uptrend

  
  BloggingStocks — Authority: 670
  Filed under: Stocks to Buy Celgene Corps ( CELG ) stock has encountered resistance at $58, but Im nevertheless reiterating my buy rating for the companys shares, first recommended on June 19, 2009 at a price of $46.94. Heres why: Look for Celgenes FY2010 revenue to increase 20-23%, on top of a likely a 15-20% ...
  9 hours ago

• Celgene Scores with Multiple Myeloma Treatment Revlimid

  
  SeekingAlpha.com: Home Page — Authority: 641
  Zacks.com submits: Celgene Corporation ( CELG ) announced recently that initial results from a late-stage study in multiple myeloma (MM) patients revealed that those treated with Revlimid underwent a 58% reduction in disease progression compared to placebo. The positive results caused shares of Celgene to close ...
  10 hours ago

• Celgene Corp.

  
  The Boston Globe | Boston.com — Authority: 733
  Celgene jumped after the company said data from a study show its drug Revlimid slowed the progression of multiple myeloma. The study, conducted by the National Cancer Institute, involves a procedure where stem cells are removed from a patient’s bone marrow before chemotherapy, then reintroduced after chemotherapy. ...
  3 days ago

• Celgene Shares Jump on Revlimid Test Success

  
  FOXNews.com — Authority: 930
  Celgenes drug trial was stopped after proven effective.
  3 days ago

• Celgene Blood Cancer Drug Found Effective

  
  BloggingStocks — Authority: 670
  Filed under: Major movement , Good news , Options , Technical Analysis Celgene ( CELG - option chain ) shares are rising today after a late-stage study of its blood cancer drug Revlimid was found to be so effective that the study was stopped early . If you think that the stock wont fall by too much in the ...
  3 days ago

• Overheard on StockTwits: $GOOG Gets the Munchies

  
  Howard Lindzon — Authority: 542
  Each day we dig into the StockTwits stream and pull out the morning buzz.  Here’s what we found today: Last night rumors came out that $ GOOG is looking to buy $ YELP for half a billion dollars!  $ GOOG has been quite a busy acquirer lately: $ CELG is a big mover today – up almost 10%.  ...
  3 days ago

• Top 10 Analyst Upgrades, Downgrades, Initiations (AOL, BP, CELG, EMC, MU, NTRS, NTAP, POT, RIMM)

  
  24/7 Wall St. — Authority: 712
  These are this Friday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls:AOL Inc. (NYSE: AOL) Started as Neutral at Goldman Sachs.BP plc (NYSE: BP) Raised to Buy at Goldman Sachs.Celgene Corp. (NASDAQ: CELG) Started as Buy at Jefferies.EMC Corp. (NYSE: EMC) Raised to Conviction ...
  3 days ago

• (CELG) Celgene Drug Meets Study Goal

  
  Stock Blog Hub — Authority: 459
  Celgene Corp. ( CELG ) recently disclosed that its drug candidate, apremilast, for treating patients with moderate-to-severe plaque-type psoriasis, met key goals in a mid-stage study (n=352). The multi-center study, in which apremilast reduced the severity of moderate-to-severe psoriasis, saw patients receiving 10 ...
  5 days ago

• Safety Dogs Elan Alzheimers Drug; Seattle Genetics Finds New Partner: BioBuzz

  
  TheStreet.com — Authority: 469
  Elan is forced to cut high doses of its Alzheimers drug ELND005 from a mid-stage study, while Seattle Genetics hooks up with a Japanese drug maker.
  6 days ago

• Gilead Discontinues Blood Pressure Drug

  
  TheStreet.com — Authority: 469
  The setback for darusentan raises doubts about Gileads $2.5 billion purchase of Myogen three years ago.
  6 days ago

• Human Genomes CEO: Biotechs Best 09

  
  TheStreet.com — Authority: 469
  Human Genome Sciences CEO Thomas Watkins is Adam Feuersteins Best Biotech CEO of the Year for 2009.
  1 week ago

• Making and Breaking Biotech Deals

  
  SeekingAlpha.com: Home Page — Authority: 641
  The Burrill Report submits: by MARIE DAGHLIAN Celgene ( CELG ) beefed up its blood cancer pipeline with the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in cash plus $300 million in future U.S. and international regulatory milestone payments. Gloucester’s cancer treatment Istodax ...
  1 week ago

• Will 2009s Losers Become 2010s Winners?

  
  SeekingAlpha.com: Home Page — Authority: 641
  Alan Brochstein , CFA submits: Last year, only 22 of the companies in the S&P 500 were able to manage gains (DV was added to the index this year). As you can see in their returns thus far in 2009, only two of them have managed to beat the markets 22.5% increase this year: Given the lack of persistence ...
  1 week ago

• Cubist moves to buy Calif. drug maker

  
  The Boston Globe | Boston.com — Authority: 733
  Cubist Pharmaceuticals Inc. , leaping into the biotech deal-making bazaar, is set to disclose today that it will spend up to $402.5 million to buy a California company that is developing an antibiotic to fight so-called superbugs.
  1 week ago

• Key Biotech Short Selling Changes in November (AMGN, BIIB, CELG, GILD, GENZ, GERN, LIFE, DNDN, HGSI, AMLN, OSIP)

  
  BioHealth Investor — Authority: 423
  We have now seen the changes in short selling in biotech stocks via the late-November short interest report from NASDAQ.  This marks the changes seen at the November 30, 2009 settlement date versus a November 13 settlement date.  We have given short interest data on Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. ...
  1 week ago

• (CELG) Celgene Corporation Presents Revlimid Data

  
  Stock Blog Hub — Authority: 459
  Celgene Corporation ( CELG ) announced recently that its cancer drug Revlimid reduced the risk of progression of the disease in newly diagnosed patients with multiple myeloma (MM) by 50%.  The data was presented at the 51st American Society of Hematology’s annual meeting in New Orleans. The data from a ...
  1 week ago

• (ONXX) Onyx Pharmaceuticals gets Positive Data

  
  Stock Blog Hub — Authority: 459
  Recently, Onyx Pharmaceuticals ( ONXX ) came out with positive data from a phase IIb study of carfilzomib at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. We are pleased to see that carfilzomib was found to be well-tolerated in heavily pre-treated relapsed and refractory ...
  1 week ago

• High Hopes Remain for Celgenes Revlimid

  
  SeekingAlpha.com: Home Page — Authority: 641
  EP Vantage submits: Hotly anticipated data from a big trial of Celgene’s ( CELG ) Revlimid in multiple myeloma were released at the American Society of Hematology (Ash) yesterday and, as is often the case, prompted more questions that answers. This is partly because the study, called MM-015, has not finished yet, ...
  1 week ago

• Tuesday Options Recap

  
  SeekingAlpha.com: Home Page — Authority: 641
  Frederic Ruffy submits: Sentiment Global equity markets are back under fire after both Standard & Poors and Fitch downgraded Greek government issued debt, sending stock benchmarks sharply lower across Europe. Meanwhile, Dubai stocks tumbled after Moodys downgraded six government related-issuers. The credit ...
  1 week ago

• CELG, KIM, BF.B, NPBC, DVA, FMS, GME, TEL Popular Stocks

  
  Ub News — Authority: 523
  U.S. stocks dropped for a second day as a reduction in Greece’s debt rating and a $3.65 billion loss by a Dubai developer added to concern that global credit markets are struggling to recover. The Dow Jones Industrial Average slid 0.98% to 10289, the S&P 500 dropped 0.95% to 1093 and the Nasdaq Composite fell ...
  1 week ago

Comments about CELG